AbbVie reported positive Phase 3 results for its T-cell engager etentamig in relapsed/refractory multiple myeloma. The company said the bispecific improved response rates and progression-free survival compared with control, a key dual readout for a field where durability and depth of response drive differentiation. For sponsors in myeloma, Phase 3 success can quickly reshape trial strategy for subsequent-line competition, particularly as T-cell engagers expand beyond earlier settings. The report also strengthens AbbVie’s position in a crowded bispecific landscape where confirmatory datasets determine the pace of regulatory filings. The company framed the update as clinically meaningful, signaling intent to build toward registration-level evidence as next steps are planned.